$-630.85
(Market cap
$34 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
96.2 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-18 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
2.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
108,063,000
5 Years Aggregate
CFO
$-456.53 Mln
EBITDA
$-478.56 Mln
Net Profit
$-558.55 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
LianBios - ADR
| -93.4 | -15.2 | -92.8 | -86.6 | -- | -- | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
LianBios - ADR
| 172.6 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
LianBios - ADR
|
0.3 | 34.5 | 0.0 | -88.0 | -- | -39.7 | -- | 0.2 |
| 2.7 | 125.0 | 0.0 | -112.7 | -- | -58.9 | -- | 0.8 |
Shareholding Pattern
View DetailsAbout LianBios - ADR
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of... obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey. Read more
-
Founder & Executive Chairman
Mr. Konstantin Poukalov
-
Founder & Executive Chairman
Mr. Konstantin Poukalov
-
Headquarters
Princeton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for LianBios - ADR
What is the current share price of LianBios - ADR Today?
The share price of LianBios - ADR is $0.30 (NASDAQ) as of 18-Apr-2024 09:30 EDT. LianBios - ADR has given a return of -86.59% in the last 1 years.
What is the current PB & PE ratio of LianBios - ADR?
Since, TTM earnings of LianBios - ADR is negative, P/E ratio is not available.
The P/B ratio of LianBios - ADR is 0.15 times as on 18-Apr-2024, a 97 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2022 |
-- |
-- |
What is the 52 Week High and Low of LianBios - ADR?
The 52-week high and low of LianBios - ADR are Rs -- and Rs -- as of 08-Sep-2026.
What is the market cap of LianBios - ADR?
LianBios - ADR has a market capitalisation of $ 34 Mln as on 18-Apr-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in LianBios - ADR?
Before investing in LianBios - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.